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Abstract The seminal description of the cellular restriction factor APOBEC3G and its
antagonism by HIV-1 Vif has underpinned two decades of research on the host-virus interaction.
We recently reported that HIV-1 Vif is also able to degrade the PPP2R5 family of regulatory
subunits of key cellular phosphatase PP2A (PPP2R5A-E; Greenwood et al., 2016; Naamati et al.,
2019). We now identify amino acid polymorphisms at positions 31 and 128 of HIV-1 Vif which
selectively regulate the degradation of PPP2R5 family proteins. These residues covary across HIV-1
viruses in vivo, favouring depletion of PPP2R5A-E. Through analysis of point mutants and naturally
occurring Vif variants, we further show that degradation of PPP2R5 family subunits is both
necessary and sufficient for Vif-dependent G2/M cell cycle arrest. Antagonism of PP2A by HIV-1 Vif
is therefore independent of APOBEC3 family proteins, and regulates cell cycle progression in HIV-
infected cells.
Introduction
The canonical function of HIV-1 Vif is to recruit the cellular restriction factor APOBEC3G for CUL5 E3
ligase and ubiquitin-proteasome-dependent degradation in infected cells, preventing APOBEC3G
encapsidation and enhancing virion infectivity (Conticello et al., 2003; Kobayashi et al., 2005;
Marin et al., 2003; Mehle et al., 2004; Sheehy et al., 2002; Sheehy et al., 2003; Stopak et al.,
2003; Yu et al., 2003). This interaction is very likely to be important in vivo, because the ability of
Vif to antagonise APOBEC3G and its homologues is broadly conserved across lentiviral phylogeny,
and has driven co-evolution of the mammalian APOBEC3 family (Compton et al., 2013;
Nakano et al., 2017).
The other cell biological phenotype associated with Vif in multiple studies is the induction of G2/
M cell cycle arrest (DeHart et al., 2008; Evans et al., 2018; Izumi et al., 2010; Sakai et al., 2006;
Wang et al., 2007; Zhao et al., 2015). Vif-dependent cell cycle arrest does not require expression
of APOBEC3 family proteins, but is reliant on lysine-48 ubiquitination and the same CUL5 E3 ligase
complex recruited by Vif to deplete APOBEC3G (DeHart et al., 2008). It has therefore been sus-
pected to reflect ubiquitination and degradation of an unknown cellular factor involved in cell cycle
progression (DeHart et al., 2008). Why only certain HIV-1 Vif variants mediate this effect
(Evans et al., 2018; Zhao et al., 2015), and how widely conserved it is across the lentiviral lineage,
have remained unclear.
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We have recently discovered that, in addition to APOBEC3 family proteins, Vif is also able to
degrade the B56 family of regulatory subunits of the ubiquitous heterotrimeric serine-threonine
phosphatase PP2A (PPP2R5A-E) in HIV-1-infected CEM-T4 T cells (Greenwood et al., 2016) and pri-
mary human CD4+ T cells (Naamati et al., 2019). Together with PP1, PP2A is one of the major cellu-
lar serine-threonine phosphatases (Nasa and Kettenbach, 2018). Specificity of the PP2A
holoenzyme is determined by the bound regulatory subunit, and targets of PP2A-B56 have been
implicated in a host of cellular processes, including the regulation of mitotic kinases and cell cycle
progression (Foley et al., 2011; Grallert et al., 2015; Vallardi et al., 2019; Yang and Phiel, 2010).
The ability of Vif to degrade PPP2R5 subunits (illustrated for PPP2R5D in Figure 1A) is shared by
Vif variants from diverse primate and non-primate lentiviruses (Greenwood et al., 2016), suggesting
a beneficial effect on viral replication in vivo. In theory, however, depletion of PPP2R5A-E could be
dependent on or secondary to the phylogenetically conserved ability of Vif to antagonise APOBEC3
family proteins. To demonstrate that these functions are autonomous and have therefore been inde-
pendently selected, we now screen a library of rationally designed Vif point mutants, and identify
amino acid substitutions at residues 31 and 128 which clearly separate APOBEC3 and PPP2R5 family
protein depletion. We further show that antagonism of PP2A explains the ability of Vif to cause cell
cycle arrest, and that this requires efficient depletion of all PPP2R5 family subunits. Naturally occur-
ring polymorphisms of residues 31 and 128 correlate with the ability of HIV-1 Vif variants to cause
cell cycle arrest, and reveal evidence of selection pressure for PPP2R5A-E depletion in vivo.
Results
Flow cytometric screen identifies mutations in HIV-1 Vif which separate
PPP2R5B and APOBEC3G depletion
To determine whether antagonism of PPP2R5 and APOBEC3 family proteins are independent func-
tions of Vif, we first used the published structure of the Vif-CUL5 complex (Guo et al., 2014) to con-
struct a library of 34 HIV-1 NL4-3 Vif variants with point mutations in solvent-exposed residues,
focussing predominantly on regions distant from known APOBEC3 family protein interaction interfa-
ces (Figure 1B and Figure 1—figure supplement 1A, residues highlighted in yellow). None of these
mutations is predicted to cause protein misfolding, nor interfere with the interactions between Vif
and other members of the Vif-CUL5 E3 ligase complex (CBF-b, CUL5, ELOB and ELOC).
Amongst the five PPP2R5 family subunits, we previously showed that depletion of PPP2R5B is
most conserved across Vif variants from HIV-1/2 and the non-human primate lentiviruses
(Greenwood et al., 2016). We therefore transfected our library into HEK 293T cells (293Ts) stably
expressing HA-tagged PPP2R5B or APOBEC3G, and used flow cytometry to quantify PPP2R5B and
APOBEC3G depletion by each Vif variant (Figure 1—figure supplement 1B–C and Figure 1—figure
supplement 2A–C). As well as indicating preserved APOBEC3 family substrate recruitment, the abil-
ity to deplete APOBEC3G served as a control for unanticipated effects on Vif expression or stability,
or assembly of the Vif-CUL5 complex.
We discovered several Vif mutants to be defective for PPP2R5B depletion (Figure 1C). Vif protein
expression levels were similar (Figure 1—figure supplement 3), but some mutations affected resi-
dues already known to be required for depletion of APOBEC3G (K26, Y44, W70) (Letko et al.,
2015) or APOBEC3C/F (R15) (Letko et al., 2015; Nakashima et al., 2016; Figure 1D and Figure 1—
figure supplement 2C). Conversely, Vif variants with mutations in residues Y30/I31, R33/K34 and
I128 were defective for PPP2R5B depletion, retained the ability to antagonise APOBEC3G, and had
not been implicated in APOBEC3C/F depletion. These residues are grouped in three similarly orien-
tated patches on the Vif surface (Figure 1B, residues highlighted in red). Aiming to identify Vif var-
iants specifically defective for PPP2R5 subunit depletion, we therefore focused on mutations in
residues I128, I31 and R33/K34 for further evaluation, including representatives from each patch.
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Figure 1. Flow cytometric screen of HIV-1 Vif point mutants. (A) Depletion of endogenous PPP2R5D by HIV-1 Vif. CEM-T4s were transduced with
lentiviruses encoding either EGFP-SBP-DLNGFR (Ctrl) or EGFP-P2A-Vif (Vif) at an MOI of 3, then lysed in 2% SDS and analysed by immunoblot with anti-
Vif, anti-PPP2R5D and anti-b-actin (loading control) antibodies after 48 hr. Green arrows, Ctrl vs Vif. (B) Solvent-accessible surfaces of Vif (pale blue) in
complex with CUL5 (dark grey), ELOB/C (grey) and CBF-b (light grey). Residues highlighted in yellow were targeted in our library of point mutants (total
Figure 1 continued on next page
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Residues 128 and 31 of HIV-1 Vif differentially regulate APOBEC3 and
PPP2R5 family protein depletion
As well as APOBEC3G, other APOBEC3 family members (such as APOBEC3F and APOBEC3H haplo-
type II) are also able to restrict HIV replication (Feng et al., 2014), and Vif recruits different APO-
BEC3 family members for degradation using distinct binding surfaces (Binka et al., 2012;
Chen et al., 2009; Dang et al., 2009; Gaddis et al., 2003; Harris and Anderson, 2016; He et al.,
2008; Letko et al., 2015; Mehle et al., 2007; Nakashima et al., 2016; Ooms et al., 2017;
Richards et al., 2015; Russell and Pathak, 2007; Simon et al., 2005; Yamashita et al., 2008). In
addition, Vif variants from HIV-1/2 and the non-human primate lentiviruses differ in their abilities to
deplete different PPP2R5 family subunits (Greenwood et al., 2016). We therefore sought to deter-
mine whether the mutations we found to separate depletion of PPP2R5B and APOBEC3G have simi-
lar effects on other family members.
First, we tested the ability of Vif mutants lacking the ability to deplete PPP2R5B to deplete HA-
tagged APOBEC3F in 293Ts, similar to our initial flow cytometry screen (Figure 1—figure supple-
ment 4A–C). As previously reported (Letko et al., 2015; Nakashima et al., 2016), mutation of R15
resulted in loss of activity against APOBEC3F. The RK33/34AA mutant was also partially impaired,
but other mutants retained full activity against APOBEC3F. APOBEC3H haplotype II was not exam-
ined, because wildtype NL4-3 Vif (on which our Vif mutant library was based) is unable to deplete
this APOBEC3 family member (Binka et al., 2012; Ooms et al., 2013; Zhao et al., 2015).
To avoid the possibility of over-expression artefacts, we next focussed on endogenous APOBEC3
and PPP2R5 family proteins expressed in CEM-T4 T cells (CEM-T4s). These cells were transduced
with the panel of I31, I128 and R33/K34 Vif mutants found in our flow cytometry screens to be spe-
cifically defective for PPP2R5B depletion, together with a Y44 mutant (also defective for APOBEC3G
depletion) to serve as a control.
Levels of an indicative PPP2R5 subunit for which a reliable antibody is available (PPP2R5D, as in
Figure 1A) were then measured by immunoblot (Figure 2A). As expected WT Vif was able to fully
deplete PPP2R5D (lane 3). Conversely, mutations in residues I128, I31, R33/K34 and Y44 all restored
PPP2R5D levels (lanes 4–9). Interestingly, the I128A (lane 4) and Y44A (lane 9) mutations only
showed a partial rescue, suggesting a differential effect on different PPP2R5 subunits (PPP2R5B vs
PPP2R5D). In addition, mutations in residues R33/K34 (lanes 7–8) were associated with lower levels
of Vif expression (Figure 2A).
Validated antibodies capable of detecting and differentiating endogenous levels of all APOBEC3
and PPP2R5 family proteins are not available. We therefore evaluated the activity of a similar panel
of Vif mutants using a tandem mass tag (TMT)-based functional proteomic approach (Figure 2B).
CEM-T4 cells were transduced with different Vif mutants at a multiplicity of infection (MOI) of 3
(range 94.1–98.7% transduced cells), then subjected to whole cell proteome analysis after a further
48 hr.
In total, we identified 8781 proteins (Figure 2—source data 1), including all 5 PPP2R5 family sub-
units (PPP2R5A/B/C/D/E) and 5 out of 7 APOBEC3 family members (B/C/D/F/G; not A/H). This
Figure 1 continued
34). Residues highlighted in red specifically affected the depletion of PPP2R5B, but not APOBEC3G. (C–D) Depletion of PPP2R5B (C) or APOBEC3G (D)
by selected Vif point mutants. 293Ts stably expressing HA-tagged PPP2R5B or APOBEC3G were transfected with constructs encoding EGFP-P2A-Vif,
then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr (see Figure 1—figure
supplement 1B–C). For each Vif point mutant, abundance of PPP2R5B or APOBEC3G is shown as a ratio of A4647 fluorescence in GFP+ (transfected,
Vif+) to GFP- (untransfected, Vif-) cells, after deducting background fluorescence of control 293Ts (no HA-tagged protein expression). Individual data
points represent biological replicates (minimum 3). Mean values with standard error of the mean (SEM) are indicated. Vif point mutants specifically
affecting the depletion of PPP2R5B are highlighted in red. Ctrl, control constructs encoding EGFP or EGFP-SBP-DLNGFR. Data for other Vif point
mutants are shown in Figure 1—figure supplement 2A–B. Green arrows, Ctrl vs Vif WT. (E) Representative data from (C–D). Green, GFP+, transfected
cells (Vif+); grey, GFP-, untransfected cells (Vif-); dotted line, background staining of control 293Ts (no HA-tagged protein expression).
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Further details for site-directed mutagenesis and flow cytometric screen.
Figure supplement 2. Complete results of flow cytometric screen.
Figure supplement 3. Stability of selected Vif point mutants in 293Ts.
Figure supplement 4. Depletion of APOBEC3F by selected Vif point mutants.
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Figure 2. Depletion of endogenous APOBEC3 and PPP2R5 family proteins by HIV-1 Vif point mutants. (A) Depletion of endogenous PPP2R5D by
selected Vif point mutants. CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then lysed in 2% SDS and analysed by
immunoblot with anti-Vif, anti-PPP2R5D and anti-b-actin (loading control) antibodies after 48 hr. Ctrl, control construct encoding EGFP-SBP-DLNGFR. (B)
Overview of proteomic experiment 1 (selected Vif point mutants). CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3,
Figure 2 continued on next page
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concords with previous data suggesting that APOBEC3A is restricted to myeloid cells (Berger et al.,
2011; Koning et al., 2009; Peng et al., 2007; Refsland et al., 2010), and neither APOBEC3A nor
APOBEC3H are expressed in CCRF-CEM cell lines at the mRNA level (Refsland et al., 2010). APO-
BEC3B is not antagonised by Vif (Doehle et al., 2005; Greenwood et al., 2016; Hultquist et al.,
2011; Naamati et al., 2019), and is therefore not considered further.
As expected, all Vif mutants tested were defective for PPP2R5B depletion, and the Y44A mutant
was also defective for APOBEC3G depletion (Figure 2C–D). In addition, and consistent with our
immunoblot analysis (Figure 2A), substitutions of I128 led to loss of activity against PPP2R5A, with
relatively preserved activity against PPP2R5C-E. Conversely, substitution of I31 led to a reciprocal
pattern, with loss of activity against PPP2R5C-E, but relatively preserved activity against PPP2R5A.
Substitutions of R33/K34 led to loss of activity against all PPP2R5 subunits, but were again associ-
ated with lower levels of Vif expression (Figure 2—figure supplement 1), and accompanied by par-
tial loss of activity against APOBEC3 family proteins, particularly APOBEC3F (mirroring our flow
cytometry data, Figure 1—figure supplement 4A–C). In conclusion, therefore, mutations in residues
128 and 31 separate PPP2R5 and APOBEC3 family depletion without affecting Vif stability, and dif-
ferentially regulate the 5 PPP2R5 family members.
Depletion of PPP2R5 family subunits is necessary for Vif-dependent cell
cycle arrest
We previously showed that expression of Vif results in extensive remodelling of the phosphopro-
teome in HIV-infected cells, including activation of the aurora kinases AURKA and AURKB, effects
we attributed to PP2A antagonism (Greenwood et al., 2016; Naamati et al., 2019). As expected,
transduction of CEM-T4s with WT Vif resulted in increased AURKA/B T loop phosphorylation
(Figure 3A, lane 3). Conversely, Vif mutants with impaired ability to antagonise PPP2R5 family subu-
nits were unable to trigger AURKA/B phosphorylation (Figure 3A, lanes 4–7).
Together with APOBEC3 family antagonism, it has been known for >10 years that certain Vif var-
iants (including NL4-3 Vif) are also able to induce G2/M cell cycle arrest, and that this is dependent
on CUL5 E3 ligase recruitment and the ubiquitin-proteasome system (DeHart et al., 2008;
Evans et al., 2018; Izumi et al., 2010; Sakai et al., 2006; Wang et al., 2007; Zhao et al., 2015).
The Vif substrate explaining this phenomenon has, however, remained obscure.
Since both PP2A-B56 (PP2A heterotrimers incorporating one of the B56 family of regulatory subu-
nits, PPP2R5A-E) and aurora kinases are required to coordinate mitotic progression (Foley et al.,
2011; Grallert et al., 2015; Nasa and Kettenbach, 2018; Vallardi et al., 2019), we hypothesised
that depletion of PPP2R5 family subunits may explain Vif-dependent cell cycle arrest, and that Vif
mutants with impaired activity against PPP2R5 family subunits may also be defective for this pheno-
type. To test this hypothesis, we first interrogated our proteomic dataset. As predicted, WT Vif led
to elevated levels of cyclin B1, indicative of G2/M arrest (Figure 3B). Conversely, elevation of cyclin
B1 was reduced or abolished in the presence of Vif mutants lacking the ability to deplete PPP2R5
family subunits.
To confirm this result and formally evaluate cell cycle progression, we measured DNA content of
CEM-T4s 48 hr after transduction with WT or mutant Vif variants. Again, WT Vif, but not Vif mutants
lacking the ability to deplete PPP2R5 subunits, caused G2/M arrest (Figure 3C–D). As a control, two
other Vif mutants (F39A and D61A) which retained the ability to antagonise PPP2RB (Figure 1—
Figure 2 continued
then analysed by TMT-based quantitative proteomics after 48 hr. Mock_1/2/3, biological replicates. Ctrl, control construct encoding EGFP-SBP-D
LNGFR. (C–D) Depletion of endogenous PPP2R5 family (C) or APOBEC3 family (D) proteins by selected Vif point mutants in cells from (B). For each Vif
point mutant, abundance of respective PPP2R5 or APOBEC family members is shown as a ratio to the mean abundance of the same family member in
the three mock-transduced samples. Significant outliers from the distribution of abundances in mock-transduced samples are highlighted (see Materials
and methods and Figure 2—figure supplement 2 for further details). *p<0.05.
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Source data 1. Complete data from proteomic experiment 1 (selected Vif point mutants).
Figure supplement 1. Stability of selected Vif point mutants in CEM-T4s.
Figure supplement 2. Calculation of t-scores and p-values.
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Figure 3. Regulation of cell cycle by HIV-1 Vif point mutants. (A) Phosphorylation of aurora kinases in the presence of selected Vif point mutants. CEM-
T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then lysed in 2% SDS and analysed by immunoblot with anti-Vif, anti-
phospho-AURK, anti-total AURKB and anti-p97 (loading control) antibodies after 48 hr. Ctrl, control construct encoding EGFP-SBP-DLNGFR. (B)
Regulation of cyclin B1 by selected Vif point mutants in cells from proteomic experiment 1 (Figure 2B). For each Vif point mutant, abundance of cyclin
B1 is shown as a ratio to the mean abundance in the three mock-transduced samples. Significant outliers from the distribution of abundances in mock-
transduced samples are highlighted (see Materials and methods for details). *p<0.05; **p<0.05. (C–D) Regulation of cell cycle by selected Vif point
mutants. CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then fixed in 90% methanol, stained with 7-AAD and
analysed by flow cytometry after 48 hr. Representative data (C) from three biological replicates (D) are shown. For each Vif point mutant, the fraction of
cells in G2/M is shown as a ratio to the fraction of cells in G2/M in mock-transduced cells. Individual data points reflect biological replicates. Mean
values with SEM are indicated. Significant differences compared with mock-transduced cells are highlighted (t-tests). *p<0.05. Ctrl, control construct
encoding EGFP-SBP-DLNGFR.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Additional controls for cell cycle analysis (Vif point mutants).
Figure supplement 2. Depletion of endogenous DPH7 and FMR1 by selected Vif point mutants.
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figure supplement 2A), also retained the ability to cause cell cycle arrest (Figure 3—figure supple-
ment 1).
In addition to APOBEC3 and PPP2R5 family proteins, we recently showed that NL4-3 Vif is also
able to target FMR1 and DPH7 (Naamati et al., 2019). Both I128A and I128D point mutants retain
the ability to deplete these proteins (Figure 3—figure supplement 2), but are unable to mediate
cell cycle arrest. Depletion of PPP2R5 family subunits, but not other Vif substrates, is therefore
required for Vif-dependent aurora kinase activation and G2/M cell cycle arrest.
Depletion of PPP2R5 family subunits is sufficient to cause cell cycle
arrest
Consistent with PPP2R5A-E depletion by Vif, inhibition of PP2A with okadaic acid causes G2/M cell
cycle arrest in CEM-T4s (Figure 4—figure supplement 1A). However, whilst relatively specific for
PP2A over other cellular phosphatases, okadaic acid does not distinguish individual PPP2R5 family
subunits, nor separate PP2A-B56 activity from the activity of other PP2A heterotrimers incorporating
regulatory subunits from different families (Swingle et al., 2007).
Since Vif-dependent cell cycle arrest is abrogated by point mutations which rescue quite distinct
PPP2R5 subunits (compare Figure 2C and Figure 3D), some functional redundancy between the dif-
ferent B56 family members seems likely. Indeed, all PPP2R5 family subunits share a well conserved
substrate-binding pocket (Hertz et al., 2016; Wang et al., 2016), and previous studies have sug-
gested functional equivalence in mitosis (Foley et al., 2011; Lee et al., 2017). Conversely, another
more recent study suggested topological restriction of PPP2R5 subunit activity within cells
(Vallardi et al., 2019). We therefore sought to test the requirement for different PPP2R5 subunits
for cell cycle progression using combinatorial knockdowns. To permit this approach, we used HeLa
cells (HeLas) as a model system.
First, we confirmed that, as in CEM-T4s, expression of WT NL4-3 Vif in HeLas causes cell cycle
arrest (Figure 4—figure supplement 1B). Likewise, mRNA expression levels of individual PPP2R5
subunits were determined by quantitative real-time PCR (qRT-PCR), and found to be similar between
cell types, with PPP2R5B much lower than other subunits (Figure 4—figure supplement 2A). Next,
we transfected HeLas with siRNA targeting individual PPP2R5 subunits, or a pool of siRNA simulta-
neously targeting all subunits (same total siRNA concentration). Strikingly, we only observed cell
cycle arrest when all subunits were knocked down together (Figure 4A–B, ‘pool’). Indistinguishable
results were seen for two independent panels of PPP2R5 family subunit siRNAs, and efficiency of
siRNA knockdown was confirmed by qRT-PCR (Figure 4—figure supplement 2B).
To confirm that knockdown of all PPP2R5 subunits is necessary for cell cycle arrest, we repeated
the experiment using pools of siRNA targeting 4 out of 5 PPP2R5 subunits (‘minus one’). Again, and
with the exception of PPP2R5B, cell cycle arrest was only observed when all subunits were knocked
down together (Figure 4C–D). Interestingly, near-identical results were previously reported from
RPE1 cells (Lee et al., 2017).
That depletion of PPP2R5B is neither sufficient (Figure 4A–B) nor required (Figure 4C–D) in this
setting may reflect low expression of PPP2R5B (Figure 4—figure supplement 2A), consistent with
previous protein-level data from HeLas (Geiger et al., 2012). To test this hypothesis, we generated
HeLa cells expressing exogenous PPP2R5B at similar levels to other PPP2R5 subunits (Figure 4—fig-
ure supplement 2C). As predicted, transfection of a pool of siRNA targeting PPP2R5A, C D and E
(but not B) caused cell cycle arrest in wildtype HeLas, but not HeLas over-expressing PPP2R5B (Fig-
ure 4—figure supplement 2D–E, compare with Figure 4C–D).
Finally, knockdown of FMR1 and DPH7 (Figure 4—figure supplement 3) did not cause cell cycle
arrest. Taken together, these observations therefore explain why efficient depletion of all PPP2R5
subunits is required to cause cell cycle arrest, and why Vif variants with impaired activity against any
PPP2R5 subunit are defective for this phenotype.
Naturally occurring vif variants phenocopy I31 and I128 point mutants
The ability to cause G2/M cell cycle arrest is known to vary between naturally occurring HIV-1 Vif var-
iants from clade B viruses (such as NL4-3 and HXB2), as well as viruses from other clades
(Evans et al., 2018; Zhao et al., 2015). We therefore examined conservation of residues 31, 33/34
and 128 across 2171 clade B HIV-1 Vif sequences available from the Los Alamos National Laboratory
Marelli et al. eLife 2020;9:e53036. DOI: https://doi.org/10.7554/eLife.53036 8 of 30
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Figure 4. Regulation of cell cycle by depletion of PPP2R5 family subunits. (A–B) Regulation of cell cycle by individual vs pooled PPP2R5A-E siRNA.
HeLas were transfected with the indicated siRNA, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr.
Representative data (A) from three biological replicates (B) for each of 2 panels of siRNA are shown. For each condition, the fraction of cells in G2/M is
shown as a ratio to the fraction of cells in G2/M in mock-transfected cells. Individual data points reflect biological replicates. Mean values with SEM are
Figure 4 continued on next page
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Web Alignments database (Figure 5A). Similar results were obtained when 3412 Vif sequences from
all (any clade, including B) non-recombinant HIV-1 M group viruses were considered (Figure 5—fig-
ure supplement 1).
Interestingly, residues 31 (I or V), 33 (K, G or R) and 128 (I or R, or less commonly L or V) all
showed obvious polymorphism, with NL4-3 Vif encoding the commonest amino acids at positions 31
(I) and 128 (I), and the second commonest amino acid at position 33 (R). We therefore evaluated
each of the common polymorphisms as single point mutations on a background of NL4-3 Vif using
our flow cytometric screen. Conservative substitutions in positions 31 and 128 partially impaired the
ability of NL4-3 Vif to deplete PPP2R5B (I31V, I128V and I128L), whereas I128R resulted in more
marked impairment (Figure 5B). Likewise, R33K, but not R33G, was well tolerated.
To evaluate these polymorphisms in their natural context, we tested Vif variants from two further
clade B HIV-1 viruses in our flow cytometric assay: the HIV-1 reference strain HXB2 (encoding 31V,
33G and 128I), and the macrophage-tropic patient isolate YU2 (encoding 31I, 33G and 128R). As a
control, we also included a Vif variant from the clade B transmitted founder virus CH470 (encoding
31I, 33K and 128I, similar to NL4-3 Vif) (Figure 5C). Consistent with the observed substitutions at
residues 31, 33 and 128, HXB2 and YU2 Vif variants were markedly impaired for PPP2R5B depletion,
whereas CH470 Vif was at least as active as NL4-3 Vif (Figure 5D). Depletion of APOBEC3G was pre-
served in each case (Figure 5—figure supplement 2).
To further assess the function of these variants against other APOBEC3 and PPP2R5 family mem-
bers, we again adopted a TMT-based functional proteomic approach (Figure 6A). As well as HXB2,
YU2 and CH470 Vif variants, we included NL4-3 Vif variants with corresponding point mutations at
positions 31 and 128 (I31V and I128R). In practice, since residue 127 is also polymorphic, and resi-
dues 127 and 128 together overlap a critical HIV splicing silencer (Madsen and Stoltzfus, 2005), we
combined I128R and R127Y mutations (RI127/128YR, as found in YU2 Vif and detailed in Figure 6—
figure supplement 1). Finally, to test the combinatorial effect of mutations in residues 31 and 128,
we included an NL4-3 Vif variant encoding both I31A and RI127/128YR (Vif AYR). CEM-T4 cells were
transduced with the panel of Vif variants at an MOI of 3 (range 93.9–98.4% transduced cells), then
subjected to whole cell proteome analysis after a further 48 hr.
In this experiment, we identified 8265 proteins (Figure 6—source data 1), including 4 out of 5
PPP2R5 family subunits (A/C/D/E) and 4 out of 7 APOBEC3 family members (B/C/D/G). As
expected, CH470 Vif remained fully active against all PPP2R5 (Figure 6B) and APOBEC3 (Figure 6C)
family subunits. Conversely, both YU2 and (in particular) HXB2 Vif variants were selectively impaired
for PPP2R5 depletion (Figure 6B). In each case, the differential pattern of PPP2R5 family subunit
depletion mirrored the effects of corresponding point mutations of residue 31 (HXB2 and NL4-3
I31V, mainly affecting PPP2R5C-E) or 128 (YU2 and NL4-3 RI127/128YR, mainly affecting PPP2R5A).
Interestingly, whilst qualitatively similar to the I31A, I128A and I128D Vif mutants evaluated earlier,
Vif variants with these naturally occurring polymorphisms were less severely impaired (compare
Figure 2C with Figure 6B).
As a functional readout, we tested the ability of the same panel of Vif variants to cause cell cycle
arrest. Consistent with previous reports (Evans et al., 2018; Zhao et al., 2015) and correlating with
their impaired activity against PPP2R5 family subunits, HXB2 and NL4-3 I31V Vif variants were unable
to cause cell cycle arrest (Figure 6D and Figure 6—figure supplement 2). Similarly, the potency of
YU2 and NL4-3 RI127/128YR Vif variants was greatly reduced, but not abolished. Naturally occurring
Figure 4 continued
indicated. Significant differences compared with mock-transduced cells are highlighted (t-tests). *p<0.05. ***p<0.0005. Ctrl siRNA, MISSION siRNA
Universal Negative Control #1. Blue histograms/data points, siRNA panel 1. Red histograms/data points, siRNA panel 2. (C–D) Regulation of cell cycle
by combinations of pooled PPP2R5A-E siRNA. HeLas were transfected with the indicated siRNA, then fixed in 90% methanol, stained with 7-AAD and
analysed by flow cytometry after 48 hr. Representative data (C) from three biological replicates (D) for each of 2 panels of siRNA are shown. All details
as per (A–B).
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Additional controls for cell cycle analysis (okadaic acid and Vif).
Figure supplement 2. Additional controls for cell cycle analysis (PPP2R5A-E siRNA).
Figure supplement 3. Additional controls for cell cycle analysis (DPH7 and FMR1 siRNA).
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NL4-3 Vif Vif variants
NL4-3       MENRWQVMIVWQVDRMRINTWKRLVKHHMYISRKAKDWFYRHHYESTNPKISSEVHIPLG 60
CH470       MENRWQVMIVWQVDRMRIKTWKSLVKHHMHISKKARGWFYRHHYESTHPKISSEVHIPLR 60
HXB2        MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPRISSEVHIPLG 60
YU2         MENRWQVMIVWQVDRMRIRAWKSLVKHHMYISGKARGWFYRHHYESPHPRISSEVHIPLG 60
******************.:** ******::* **:.********* :*:********* 
NL4-3       DAKLVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDPDLADQLIHLHYFDCFSESAI 120
CH470       EARLVITTYWGLHTGERDWHLGQGVSIEWRKRKYSTQVDPDLADQLIHLYYFDCFSESAI 120
HXB2        DARLVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDPELADQLIHLYYFDCFSDSAI 120
YU2         DAKLVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDPDLADQLIHLYYFDCFSESAI 120
:*:****************************::*******:********:******:***
NL4-3       RNTILGRIVSPRCEYQAGHNKVGSLQYLALAALIKPKQIKPPLPSVRKLTEDRWNKPQKT 180
CH470       RNALLGHIVSPRCEYQAGHNKVGSLQYLALTALVAPKKTKPPLPSVKKLTEDRWNKPQKT 180
HXB2        RKALLGHIVSPRCEYQAGHNKVGSLQYLALAALITPKKIKPPLPSVTKLTEDRWNKPQKT 180
YU2         RKAILGYRVSPRCEYQAGHNKVGSLQYLALTALITPKKTKPPLPSVKKLTEDRWNKPQKT 180
*:::**  **********************:**: **: ******* *************
NL4-3       KGHRGSHTMNGH 192
CH470       KGHRGSHTMSGH 192
HXB2        KGHRGSHTMNGH 192
YU2         KGHRGSRTMNGH 192
******:**.**
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Figure 5. Analysis of naturally occurring HIV-1 Vif variants. (A) Amino acid polymorphism amongst 2171 naturally occurring HIV-1 M group Vif variants
(clade B). Sequence logos (left panel) and bar chart (right panel) highlight frequencies of amino acids corresponding to residues 31, 33 and 128 of NL4-
3 Vif. In the sequence logos, polar amino acids (AAs) are depicted in green; neutral AAs, in purple; basic AAs, in blue; acidic AAs, in red; and
hydrophobic AAs, in black. An equivalent bar chart for all naturally occurring non-recombinant HIV-1 M group Vif variants (all clades) is shown in
Figure 5 continued on next page
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polymorphisms at residues 31 and 128 therefore modulate the ability of Vif to deplete PPP2R5 family
subunits, and explain why some HIV-1 Vif variants are unable to cause cell cycle arrest.
Combined I31 and I128 mutations abolish PPP2R5 family subunit
depletion and rarely occur in nature
Unlike individual mutations of residues 31 or 128, combined I31A and RI127/128YR mutations in
NL4-3 Vif (Vif AYR) completely abolished the depletion of all PPP2R5 family subunits in our proteo-
mic analysis (Figure 6B), without affecting the depletion of APOBEC3 family proteins (Figure 6C).
Since PPP2R5B and APOBEC3F were not quantitated in the proteomic experiment, we tested the
ability of Vif AYR to deplete these subunits by flow cytometry in 293Ts, including APOBE3G as a
control (Figure 6—figure supplement 3A–B). As expected, Vif AYR was able to deplete APOBEC3F
and APOBEC3G but not PPP2R5B, and failed to cause cell cycle arrest (Figure 6D).
We next sought to confirm these results in the context of viral infection by introducing the same
mutations into the NL4-3-based HIV-AFMACS molecular clone (Naamati et al., 2019). This Env-defi-
cient (single round) reporter virus encodes a SBP-DLNGFR cell surface streptavidin-binding affinity
tag, allowing facile one-step selection of infected cells with streptavidin-conjugated magnetic beads
(Antibody-Free Magnetic Cell Sorting, AFMACS) (Matheson et al., 2014). To enable analysis of cell
cycle without confounding by Vpr, a Vpr-deficient (DVpr) background was used.
To assess the function of Vif AYR against APOBEC3 and PPP2R5 family members during viral
infection, we first adopted a TMT-based functional proteomic approach to compare mock-infected
cells with cells infected with DVpr-Vif WT, DVpr-DVif or DVpr-Vif AYR viruses (Figure 7A). CEM-T4s
were infected at an MOI of 0.5 (range 29.3–48.7% infected cells), purified using AFMACS after 48 hr
(range 93.3–96.6% infected cells, Figure 7—figure supplement 1A–B), then subjected to whole cell
proteome analysis.
In this experiment, we identified 6297 proteins (Figure 7—source data 1), including 4 out of 5
PPP2R5 family subunits (A/C/D/E) but only 1 out of 7 APOBEC3 family member (C). As expected,
DVpr-Vif WT virus (Figure 7B, left panel) but not DVpr-DVif virus (Figure 7B, middle panel) was able
to deplete both APOBEC3C and PPP2R5 family proteins. Conversely, DVpr-Vif AYR virus (Figure 7B,
right panel) retained the ability to deplete APOBEC3C, but was completely inactive against PPP2R5
family proteins. As a control, the Nef and Vpu target CD4 was similarly downregulated by each virus
(Guy et al., 1987; Willey et al., 1992). To confirm a functional effect on PP2A, we then used these
viruses to infect CEM-T4 T cells, and measured their effect on cell cycle progression. Again, only
DVpr-Vif WT virus, but not DVpr-DVif or DVpr-Vif AYR viruses, was able to induce G2/M cell cycle
arrest (Figure 7C). A similar effect was observed in HIV-infected primary human CD4+ T cells (Fig-
ure 7—figure supplement 2A–B).
If the ability of Vif to antagonise PP2A is maintained by selection pressure in vivo, combinations
of unfavourable (less active against PPP2R5A-E) mutations in residues 31 and 128 (abolishing all
PPP2R5 family subunit depletion) should be rare amongst naturally occurring HIV-1 Vif variants. Fur-
thermore, if effects on viral fitness are synergistic, such combinations should occur less frequently
than predicted by chance. We therefore examined covariance of polymorphisms of residues 31 and
Figure 5 continued
Figure 5—figure supplement 1. (B) Depletion of PPP2R5B by selected Vif point mutants. 293Ts stably expressing HA-tagged PPP2R5B were
transfected with constructs encoding EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow
cytometry after 36 hr. Ctrl, control construct encoding EGFP-SBP-DLNGFR. All details as per Figure 1C. (C) Sequence alignments of selected Vif
variants. Amino acids corresponding to residues 31, 33 and 128 of NL4-3 Vif are highlighted in red (red boxes). Other residues targeted in our library of
point mutants and known to interact with APOBEC3G (green), APOBEC3C/F (orange) and APOBEC3H (blue) are also shown (as per Figure 1—figure
supplement 2C). Additional annotations (a-helices, b-sheets, Zn finger and BC-box) are based on the published Vif-CUL5 crystal structure (Guo et al.,
2014). (D) Depletion of PPP2R5B by selected Vif variants. 293Ts stably expressing HA-tagged PPP2R5B were transfected with constructs encoding
EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr. Ctrl, control
construct encoding EGFP-SBP-DLNGFR. All details as per (B) and Figure 1C.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Amino acid polymorphism amongst 3412 naturally occurring non-recombinant HIV-1 M group Vif variants (all clades).
Figure supplement 2. Depletion of APOBEC3G by selected Vif variants.
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Figure 6. Depletion of endogenous APOBEC3 and PPP2R5 family proteins by naturally occurring HIV-1 Vif variants. (A) Overview of proteomic
experiment 2 (naturally occurring Vif variants and corresponding point mutants). CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at
an MOI of 3, then analysed by TMT-based quantitative proteomics after 48 hr. Mock_1/2/3, biological replicates. Ctrl, control construct encoding EGFP.
NL4-3 AYR, NL4-3 Vif with both I31A and RI127/128YR mutations. (B–C) Depletion of endogenous PPP2R5 family (B) or APOBEC3 family (C) proteins by
Figure 6 continued on next page
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128 across the clade B HIV-1 Vif sequences available from the Los Alamos National Laboratory Web
Alignments database (Figure 7D; same 2171 sequences as Figure 5A).
Amongst these sequences, 21.8% encode 31V (less active) and 33.6% encode R128 (less active).
By chance, combinations of 31V and 128R would therefore be expected in 7.3% of sequences. Con-
versely, this combination is observed in only 5.8% of sequences. Whist this difference appears mod-
est, the association between these polymorphisms is highly statistically significant (p=0.0003,
Fisher’s exact test, Figure 7—figure supplement 3A, left panel). We observed similar, significant
under-representation when we limited our analysis to clade B viruses encoding combinations of 31I/
V and 128I/R (Figure 7—figure supplement 3A, right panel), or extended it to include Vif sequen-
ces from all (any clade, including B) non-recombinant HIV-1 M group viruses (Figure 7—figure sup-
plement 3B–C; same 3412 sequences as Figure 5—figure supplement 1).
To distinguish functional covariance of these residues from background linkage disequilibrium
(co-inheritance of polymorphisms from a common ancestor), we constructed phylogenetic trees of
all Vif variants based on Vif (Figure 7E) or Nef, Gag or Env (Figure 7—figure supplement 4A).
Regardless of the viral protein used, viruses encoding different combinations of 31/128 polymor-
phisms were scattered throughout the phylogeny, with no obvious founder effect. Again, similar
results were seen when we extended our analysis to include Vif sequences from all (any clade, includ-
ing B) non-recombinant HIV-1 M group viruses (Figure 7—figure supplement 4B).
Taken together, these data therefore provide evidence of a functional interaction between resi-
dues 31/128, and suggest significant in vivo selection pressure to maintain the ability of Vif to antag-
onise PP2A.
Discussion
The study of cellular proteins and processes targeted by HIV has provided critical insights into the
host-virus interaction. Typically, these targets have been identified piecemeal, using candidate
approaches. In contrast, we have recently adopted unbiased proteomic approaches to identify novel
substrates of HIV accessory proteins (Greenwood et al., 2016; Greenwood et al., 2019;
Matheson et al., 2015; Naamati et al., 2019). A key challenge is now to determine the biological
significance of these targets for HIV-infected cells: both whether they are important, and why they
are important.
In this study, we sought to address these questions for Vif targets PPP2R5A-E. By demonstrating
that depletion of PPP2R5 family subunits by Vif is separable from targeting of APOBEC3 family pro-
teins, we formally prove that PP2A antagonism is neither required for, nor an epiphenomenon of,
APOBEC3 family protein depletion. Combined with evidence of conservation across HIV-1 viruses
and the broader lentiviral lineage (Greenwood et al., 2016), these observations provide strong
genetic evidence for the importance of PPP2R5 depletion by Vif in vivo.
Strikingly, the critical residues for PPP2R5 depletion identified in our screen included several pre-
viously determined to be important for Vif-dependent cell cycle arrest in other, independent studies
(31, 33, 44) (DeHart et al., 2008; Zhao et al., 2015). As well as residues required for CUL5 complex
Figure 6 continued
naturally occurring Vif variants and corresponding point mutants in cells from (A). For each Vif variant or point mutant, abundance of respective PPP2R5
or APOBEC family members is shown as a ratio to the mean abundance of the same family member in the three mock-transduced samples. Significant
outliers from the distribution of abundances in mock-transduced samples are highlighted (see Materials and methods and Figure 2—figure
supplement 2 for further details). *p<0.05; **p<0.005. † Not detected in this experiment (PPP2R5B, APOBEC3F). (D) Regulation of cell cycle by
naturally occurring Vif variants and corresponding point mutants. CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3,
then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Individual data points reflect three biological replicates
(representative data, Figure 6—figure supplement 2). **p<0.005. ***p<0.0005. Ctrl, control construct encoding EGFP. NL4-3 AYR, NL4-3 Vif with both
I31A and RI127/128YR mutations. All other details as per Figure 3C–D.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. Complete data from proteomic experiment 2 (naturally occurring Vif variants and corresponding point mutants).
Figure supplement 1. Sequence of Exonic Splicing Silencer of Vpr (ESSV) in NL4-3 and YU2 Vif variants.
Figure supplement 2. Regulation of cell cycle by naturally occurring Vif variants and corresponding point mutants (representative data).
Figure supplement 3. Depletion of PPP2R5B, APOBEC3G and APOBEC3F by Vif AYR.
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Figure 7. Selective regulation of PPP2R5 family subunits during HIV-1 infection. (A) Overview of proteomic experiment 3 (viral infections). CEM-T4s were
infected with HIV-AFMACS viruses at an MOI of 0.5, then purified using AFMACS (Figure 7—figure supplement 1A–B) and analysed by TMT-based
quantitative proteomics after 48 hr. Biological replicates are shown. Vif AYR, NL4-3 Vif with both I31A and RI127/128YR mutations. (B) Protein
abundances in HIV-infected vs mock-infected cells from (A). Volcano plots show statistical significance (y-axis) vs fold change (x-axis) for 6294 viral and
Figure 7 continued on next page
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assembly (114 and 145), several additional residues (14, 36, 48 and 40) were implicated in the same
studies. Amongst these, a K36A point mutant showed an intermediate effect on PPP2R5B depletion
in our screen (Figure 1—figure supplement 2A). The other residues were not tested, because we
focussed on regions of Vif not known to be important for depletion of APOBEC3 family proteins,
and residues with solvent-exposed side chains unlikely to lead to structural disruption.
We were initially puzzled because some Vif point mutants were markedly impaired in their ability
to cause cell cycle arrest, yet retained the ability to deplete at least some PPP2R5 family subunits.
Furthermore, the ability of Vif to cause cell cycle arrest did not appear to correlate with depletion of
any one, specific PPP2R5 subunit. In fact, because efficient depletion of all PPP2R5 subunits is
required to halt cell cycle progression, these are not paradoxes at all. This same model also suggests
explanations for two related phenomena.
First, expression of HIV-1 Vif in mouse or COS cells results in depletion of PPP2R5D, but does not
cause cell cycle arrest (Evans et al., 2018). As with Vif point mutants and naturally occurring variants
in human cells, it seems likely that another PPP2R5 subunit escapes depletion in these species-mis-
matched cells. Second, we previously found the ability of Vif to antagonise at least some PPP2R5
subunits to be widely conserved (Greenwood et al., 2016), but the ability to cause cell cycle arrest
is variable amongst HIV-1 Vif variants (Evans et al., 2018; Zhao et al., 2015). Since efficient deple-
tion of all expressed PPP2R5 subunits is required to cause cell cycle arrest, escape of even a single
subunit allows cell cycle to progress.
Amongst all HIV-1 Vif sequences analysed here, the commonest single combination of residues at
positions 31 and 128 was 31I/128I, accounting for approximately 30% of Vif variants. Most of these
sequences also encode 33R or 33K and, like NL4-3 and CH470 Vif, are therefore expected to effi-
ciently degrade PPP2R5A-E, and cause cell cycle arrest. Conversely, only approximately 5% encode
31V/128R, and are therefore expected to be severely impaired for PPP2R5A-E degradation. It is
likely that most of the remaining Vif variants, like YU2 and HXB2, are active against at least some
PPP2R5 family members, but may be variably attenuated in their ability to cause cell cycle arrest.
Interestingly, naturally occurring Vif variants have also been shown to exhibit a spectrum of activity
against APOBEC3 family proteins, including variants which fail to neutralise one or more APOBEC3
family proteins (Binka et al., 2012; Iwabu et al., 2010; Mulder et al., 2008; Simon et al., 2005).
Mechanistically, hyperphosphorylation of aurora kinase substrates is expected to contribute sig-
nificantly to Vif-dependent cell cycle arrest (Foley et al., 2011). Nonetheless, PP2A is a ‘master regu-
lator’ of cell cycle (Wlodarchak and Xing, 2016), and depletion of PPP2R5A-E by Vif causes
widespread remodelling of the phosphoproteome, implying activation of multiple kinases
(Greenwood et al., 2016). Consistent with this, Vif-dependent cell cycle arrest was previously shown
Figure 7 continued
cellular proteins (no missing values). Pair-wise comparisons of mock-infected cells with cells infected with DVpr-Vif WT (left panel), DVpr-DVif (middle
panel) or DVpr-Vif AYR (right panel) viruses are shown. Proteins with Benjamini-Hochberg FDR-adjusted p values (q values)<0.05 (black crosses) or >0.05
(grey crosses) are indicated (FDR threshold of 5%). Proteins highlighted in each plot are summarised in the key. 4 out of 5 PPP2R5 family subunits (A/C/
D/E) were quantitated, but only 1 out of 7 APOBEC3 family members (C). (C) Regulation of cell cycle in HIV-infected CEM-T4s. Cells were infected with
HIV-AFMACS viruses at an MOI of 0.5, then stained with FITC-conjugated anti-LNGFR antibody, fixed in 90% methanol, stained with 7-AAD and
analysed by flow cytometry after 48 hr. Representative data (upper panels) from three biological replicates (lower panel) are shown. Green, LNGFR+
cells (HIV+); grey, LNGFR- cells (uninfected). For each virus, the fraction of HIV+ (LNGFR+) cells in G2/M is shown as a ratio to the fraction of uninfected
(LNGFR-) cells in G2/M. Individual data points reflect biological replicates. Mean values with SEM are indicated. Significant differences are highlighted
for each pair-wise comparison (t-tests). **p<0.005. (D) Pair-wise combinations of key amino acid polymorphisms amongst 2171 naturally occurring HIV-1
M group Vif variants (clade B). Frequencies of amino acids corresponding to residues 31 and 128 of NL4-3 Vif are shown. An equivalent pie chart for all
naturally occurring non-recombinant HIV-1 M group Vif variants (all clades) is shown in Figure 7—figure supplement 3B. (E) Phylogenetic tree of 795
HIV-1 M group viruses (clade B) with protein sequences available for all of Vif, Gag, Env and Nef (based on relatedness of Vif). Viruses encoding Vif
variants with I31/I128 (most active, red) and V31/R128 (least active, blue) are highlighted. Equivalent phylogenetic trees based on relatedness of Gag,
Env or Nef are shown in Figure 7—figure supplement 4A.
The online version of this article includes the following source data and figure supplement(s) for figure 7:
Source data 1. Complete data from proteomic experiment 3 (viral infections).
Figure supplement 1. AFMACS-based purification of infected cells for proteomic experiment 3 (viral infections).
Figure supplement 2. Regulation of cell cycle in HIV-infected primary human CD4+ T cells.
Figure supplement 3. Additional bioinformatics analysis.
Figure supplement 4. Additional phylogenetic trees.
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to require TP53 (Izumi et al., 2010), and several studies have identified upstream regulation of TP53
by PP2A in different systems (Ajay et al., 2010; Li et al., 2002; Yang and Phiel, 2010).
Many RNA and DNA viruses cause and are thought to benefit from cell cycle arrest (Bagga and
Bouchard, 2014). In HIV infection, G2/M cell cycle arrest was first attributed to Vpr (He et al., 1995;
Jowett et al., 1995; Rogel et al., 1995), which remains better known for this function. Early studies
suggested a positive effect of G2/M arrest on transcription from the HIV-1 LTR (Goh et al., 1998;
Gummuluru and Emerman, 1999), but more recent results have raised the possibility that cell cycle
arrest may be secondary to another Vpr-dependent process, such as antagonism of innate immunity
(Laguette et al., 2014). Nonetheless, targeting of the same cell biological process by multiple viral
accessory proteins is strong a priori evidence of biological importance in vivo.
Functional redundancy with Vpr may also help explain why Vif-dependent cell cycle arrest is not
more strictly conserved across naturally occurring HIV-1 Vif variants. In addition, key polymorphic
residues which regulate PPP2R5 antagonism may be subject to balancing selection pressures. First,
the requirement to maintain the Exonic Splicing Silencer of Vpr (ESSV) at the RNA level limits the
sequence variability tolerated at position 128 (Madsen and Stoltzfus, 2005). Second, polymor-
phisms at position 31 also regulate antagonism of APOBEC3H (Zhao et al., 2015). Indeed, at least
in some cases, the abilities of Vif to antagonise APOBEC3H and cause cell cycle arrest were found to
be mutually exclusive.
Vif-dependent cell cycle arrest correlates with viral cytopathicity (Evans et al., 2018; Sakai et al.,
2006), and was reported to enhance HIV-1 replication in vitro in a previous study using chimeric
HXB2/NL4-3 Vif variants (Izumi et al., 2010). Classic experiments comparing WT and Vif-deficient
viruses in permissive cells often examined HXB2 (Gabuzda et al., 1992) or YU2 (Gaddis et al., 2003)
viruses. Since these Vif variants are shown here to be attenuated in their activity against different
PPP2R5 subunits, manifested by a reduced ability to cause cell cycle arrest, it is likely that these stud-
ies failed to fully capture the effects of PP2A antagonism on viral infection.
As importantly, the ability to assess APOBEC3-independent effects of Vif on viral fitness in vitro
has hitherto been limited to comparisons between WT and Vif-deficient viruses on an APOBEC3-
negative background, such as the CEM-SS cell line. In contrast, the point mutants identified in this
study maintain the ability to antagonise APOBEC3 family proteins, and will therefore allow the
assessment of Vif-dependent PP2A antagonism by the community in a full range of cell types, includ-




(species) or resource Designation Source or reference Identifiers Additional information
Cell line (human) CEM-T4 T cells (CEM-T4s) NIH AIDS Reagent Program Cat. #: 117 Also known as CEM CD4+ cells
Cell line (human) THP-1 cells (THP-1s) NIH AIDS Reagent Program Cat. #: 9942 Used for cDNA library generation
Cell line (human) HeLa cells (HeLas) Lehner laboratory stocks RRID:CVCL_0030
Cell line (human) HEK 293T cells (293Ts) Lehner laboratory stocks RRID:CVCL_0063
Antibody Mouse monoclonal
BV421-conjugated anti-CD4
BioLegend Cat. #: 317434 Flow cytometry (1:50)
Antibody Mouse monoclonal
PE-conjugated anti-CD4








BioLegend Cat. #: 345103 Flow cytometry (1:50)
Antibody Mouse monoclonal
BV421-conjugated anti CD4
BioLegend Cat. #: 317434 Flow cytometry (1:50)
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Reagent type




Abcam Cat. #: ab117515 Flow cytometry (1:400)
Antibody Rabbit monoclonal
anti-PPP2R5D
Abcam Cat. #: ab188323 Immunoblot (1:5000)
Antibody Mouse monoclonal
anti-HIV-1 Vif
NIH AIDS Reagent Program Cat. #: 6459 Immunoblot (1:2500)
Antibody Rabbit polyclonal
anti-FMR1 (FMRP)
Cell Signalling Technology Cat. #: 4317 Immunoblot (1:1000)
Antibody Rabbit polyclonal
anti-DPH7
Atlas Antibodies Cat. #: HPA022911 Immunoblot (1:1000)
Antibody Mouse monoclonal
anti-b-actin
Sigma Cat. #: A5316 Immunoblot (1:20000)
Antibody Mouse monoclonal
anti-p97 (VCP)
Abcam Cat. # ab11433 Immunoblot (1:10000)
Antibody Rabbit polyclonal
anti-total AURKB
Cell Signalling Technology Cat. #: 3094 Immunoblot (1:500)
Antibody Rabbit monoclonal
anti-phospho-AURK
Cell Signalling Technology Cat. #: 2914 Immunoblot (1:500)










pHRSIN-SE-W-pSV40-puro van den Boomen et al., 2014 N/A Used as a control
Recombinant
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Invitrogen Cat. #: 18080044
Chemical
compound, drug
Lenti-X Concentrator Clontech Cat. #: 631232
Commercial
assay or kit
Dynabeads Biotin Binder Invitrogen Cat. #: 11047
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Reagent type




Human CD4 T Cells kit





Invitrogen Cat. #: 11132D
Commercial
assay or kit
S-Trap micro MS Sample
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Proteome Discoverer 2.1 Thermo Scientific RRID:SCR_014477
Software,
algorithm
R v.3.5.3 R Development Core Team, 2019 RRID:SCR_001905 https://www.R-project.org/
Software,
algorithm




WebLogo Crooks et al., 2004 RRID:SCR_010236 http://weblogo.berkeley.edu
Software,
algorithm




ggplot2 Wickham, 2009 RRID:SCR_014601 https://ggplot2.tidyverse.org
Software,
algorithm









Prism 7.0 GraphPad RRID:SCR_002798
General cell culture
CEM-T4 T cells (Foley et al., 1965) and THP-1 cells (Wu et al., 2004) were obtained directly (<1
year) from the AIDS Reagent Program, Division of AIDS, NIAD, NIH (Dr J. P. Jacobs, and Drs L. Wu
and V. N. KewalRamani, respectively), and cultured at a density of 5  105 to 2  106 cells/ml in
RPMI supplemented with 10% fetal calf serum (FCS), 100 units/ml penicillin and 0.1 mg/ml strepto-
mycin at 37˚C in 5% CO2. HeLa cells and HEK 293T cells (authenticated by STR profiling
[Menzies et al., 2018; Miles et al., 2017]) were obtained from Lehner laboratory stocks and cul-
tured in DMEM supplemented with 10% FCS, 100 units/ml penicillin and 0.1 mg/ml streptomycin at
37˚C in 5% CO2. All cells were regularly screened and confirmed to be mycoplasma negative (Lonza
MycoAlert).
Primary cell isolation and culture
Primary human CD4+ T cells were isolated from peripheral blood by density gradient centrifugation
over Lympholyte-H (Cedarlane Laboratories) and negative selection using the Dynabeads Untouched
Human CD4 T Cells kit (Invitrogen) according to the manufacturer’s instructions. Purity was assessed
by flow cytometry for CD3 and CD4 and routinely found to be 95%. Cells were activated using
Dynabeads Human T-Activator CD3/CD28 beads (Invitrogen) according to the manufacturer’s
instructions and cultured in RPMI supplemented with 10% FCS, 30 U/ml recombinant human IL-2
(PeproTech), 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37˚C in 5% CO2.
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Ethics statement
Ethical permission for this study was granted by the University of Cambridge Human Biology
Research Ethics Committee (HBREC.2017.20). Written informed consent was obtained from all vol-
unteers prior to providing blood samples.
Vectors for transgene expression
Sequences for Vif variants from NL4-3 (AF324493.2), HXB2 (K03455.1), YU2 (GenBank: M93258.1)
and CH470 (JX972238-JX972249) viruses were obtained from GenBank. The CH470 transmitted
founder (TF) Vif sequence was inferred as previously described (Fenton-May et al., 2013; Liu et al.,
2013; Parrish et al., 2013).
For co-expression of codon optimised Vif variants with EGFP, gBlocks (IDT) encoding NL4-3,
HXB2, YU2 or CH470 Vif were incorporated into pHRSIN-SE-P2A-SBP-DLNGFR-W (Matheson et al.,
2014) in place of SBP-DLNGFR by Gibson assembly between XhoI/KpnI sites (generating pHRSIN-
SE-P2A-Vif-W vectors). In these vectors, Vif variants are expressed from the Friend spleen focus-
forming virus (SFFV) promoter as EGFP-P2A-Vif, downstream of EGFP and a ‘self-cleaving’ Porcine
teschovirus-1 2A (P2A) peptide.
Complete sequences for all gBlocks are included in Supplementary file 1 (Codon-optimised Vif
variants synthesised as gBlocks). Codon optimisation was conducted using the IDT codon optimisa-
tion tool, and sequences were verified by Sanger sequencing (Source BioScience).
The parental vector (in which EGFP and the SBP-DLNGFR cell surface selection marker are
expressed from the SFFV promoter as EGFP-SBP-DLNGFR) was used here as a control. Where indi-
cated, pHRSIN-SE-W-pSV40-puro (in which EGFP is expressed from the SFFV promoter as a single
transgene) was used as an alternative control (van den Boomen et al., 2014).
To generate stable 293T cell lines for our flow cytometric screen, N-terminal 4xHA-tagged
PPP2R5B and C-terminal 4xHA-tagged APOBEC3G were expressed using pHRSIN-S-W-pGK-puro
exactly as previously described (Greenwood et al., 2016). HeLas stably expressing exogenous
PPP2R5B were generated using the same construct. C-terminal 4xHA-tagged APOBEC3F was ampli-
fied by PCR from a cDNA library generated from THP-1s using the Superscript III First-Strand Syn-
thesis System (Invitrogen) with Oligo(dT) (Invitrogen), and also expressed using pHRSIN-S-W-pGK
puro. The complete sequence is included in Supplementary file 1 (C-terminal 4xHA-tagged APO-
BEC3F coding sequence in pHRSIN-S-W-pGK puro), and was verified by Sanger sequencing (Source
BioScience).
Vif mutant library construction
To generate a library of Vif point mutants, a PCR and Gibson assembly-based approach was used to
modify codon-optimised NL4-3 Vif directly in pHRSIN-SE-P2A-Vif-W (Figure 1—figure supplement
1A).
Briefly, forward and reverse primers encoding each point mutation were designed with ~15 bp
fully complementary flanking sequences. These mutation-specific primers were used in pairwise PCR
reactions in conjunction with common primers complementary to the vector backbone, which was
cut between XhoI/KpnI sites. The two PCR products were then assembled into the vector using the
NEBuilder HiFi DNA Assembly Master Mix (NEB).
Sequences for all primers used are tabulated in Supplementary file 1 (PCR primers for Vif mutant
library construction). All sequences were verified by Sanger sequencing (Source BioScience).
HIV-1 molecular clones
HIV-AFMACS (pNL4-3-DEnv-Nef-P2A-SBP-DLNGFR; GenBank: MK435310.1) has been previously
described (Naamati et al., 2019). To introduce mutations in the native NL4-3 Vif coding sequence,
the same PCR and Gibson assembly-based approach developed for Vif mutant library construction
was used, cutting the vector backbone between AgeI/SalI sites. Where indicated, multiple mutations
were introduced sequentially.
To generate DVpr-Vif WT virus (lacking Vpr expression, but encoding WT Vif), a silent mutation
was introduced into Vif codon 173 (AGA >AGG; both encoding Arg), eliminating the Vpr start codon
in the +two reading frame. Additional point mutations were introduced to generate DVpr-Vif AYR
virus (lacking Vpr expression, but encoding Vif with I31A and R127Y/I128R mutations) and DVpr-DVif
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virus (lacking Vpr expression, and encoding two premature stop codons after the final in-frame start
codon in the Vif open reading frame).
Final Vif coding sequences for each virus are included in Supplementary file 1 (Vif coding
sequences in HIV-AFMACS viruses). Sequences were verified by Sanger sequencing (Source
BioScience).
Transient transfection
For the flow cytometric screen, 293T cells stably expressing HA-tagged PPP2R5B or APOBEC3G
were transfected with 200 ng/well control or Vif expression vector in 24-well plates using FuGENE 6
(Promega). After 36 hr, cells were harvested with trypsin-EDTA and analysed by flow cytometry.
siRNA transfection
For RNAi-mediated knockdown, HeLa cells were transfected with custom siRNA duplexes (Sigma)
using transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s
instructions.
Briefly, 2  105 cells/well were seeded in 6-well plates 24 hr prior to transfection with a total of
50 pmol/well siRNA (individual or pooled). Knockdown was verified by real-time PCR or immunoblot
24 hr post-transfection, and cells were re-seeded prior to cell cycle analysis 48 hr post-transfection
(target 50% confluency).
All siRNA target sequences used are tabulated in Supplementary file 1 (Target sequences for
RNAi). Cells not subjected to knockdown were transfected with MISSION siRNA Universal Negative
Control #1 (Sigma) at equivalent concentrations.
Viral stocks
VSVg-pseudotyped lentivector stocks were generated by co-transfection of 293Ts with pHRSIN-
based lentivector, p8.91 and pMD.G at a ratio of 2:1:1 (mg) DNA and a DNA:FuGENE 6 ratio of 1
mg:3 ml. Media was changed the next day and viral supernatants harvested and filtered (0.45 mm) at
48 hr prior to concentration with Lenti-X Concentrator (Clontech) and storage at  80˚C.
VSVg-pseudotyped HIV-AFMACS viral stocks were generated by co-transfection of 293Ts with
HIV-AFMACS molecular clones and pMD.G at a ratio of 9:1 (mg) DNA and a DNA:FuGENE 6 ratio of
1 mg:6 ml. Viral supernatants were harvested, filtered, concentrated and stored as per pHRSIN-based
lentivector stocks.
Lentivector/viral stocks were titrated by transduction/infection of known numbers of relevant tar-
get cells with known volumes of stocks under standard experimental conditions, followed by flow
cytometry for EGFP (GFP-expressing lentivectors) or SBP-DLNGFR and CD4 (HIV-AFMACS viruses)
at 48 hr to identify the fraction of transduced/infected cells (f) containing at least one transcription-
ally active provirus (EGFP positive or SBP-DLNGFR positive/CD4 low). The number of transducing/
infectious units present was then calculated by assuming a Poisson distribution (where f = 1-e-MOI).
Typically, a dilution series of each stock was tested, and titre determined by linear regression of -ln
(1-f) on volume of stock.
Transductions and infections
Primary human CD4+ T cells, CEM-T4s, HeLas and 293Ts were transduced or infected by spinocula-
tion at 800 g for 1 hr in a non-refrigerated benchtop centrifuge in complete media supplemented
with 10 mM HEPES. Stable cell lines were selected using puromycin, and 293Ts expressing HA-
tagged APOBEC3F or APOBEC3G were single-cell cloned prior to flow cytometric screening.
Antibody-Free magnetic cell sorting (AFMACS)
AFMACS-based selection of CEM-T4s using the streptavidin-binding SBP-DLNGFR affinity tag was
carried out essentially as previously described (Matheson et al., 2014; Naamati et al., 2019).
Briefly, 1  106 CEM-T4s/condition were infected with VSV-g pseudotyped HIV-AFMACS viruses at
an MOI of 0.5. 48 hr post-infection, washed cells were resuspended in incubation buffer (IB; Hank’s
balanced salt solution, 2% dialysed FCS, 1x RPMI Amino Acids Solution (Sigma), 2 mM L-glutamine,
2 mM EDTA and 10 mM HEPES) at 107 cells/ml and incubated with Dynabeads Biotin Binder (Invitro-
gen) at a bead-to-total cell ratio of 4:1 for 30 min at 4˚C. Bead-bound cells expressing SBP-DLNGFR
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were selected using a DynaMag-2 magnet (Invitrogen), washed to remove uninfected cells, then
released from the beads by incubation in complete RPMI with 2 mM biotin for 15 min at room tem-
perature (RT). Enrichment was assessed by flow cytometry pre- and post-selection.
Proteomics
Sample preparation
For TMT-based whole cell proteomic analysis of transduced or infected CEM-T4s, washed cell pellets
were lysed in 50 mM HEPES pH 8 with 5% SDS followed by 10 min (30 s on/off) sonication in a Bio-
ruptor Pico sonicator (Diagenode) at 18˚C. Lysates were quantified by BCA assay (Thermo Scientific)
and 25 mg (transduced CEM-T4s, experiments 1–2) or 10 mg (infected and AFMACS-selected CEM-
T4s, experiment 3) total protein/condition used for further analysis.
Sample volumes were equalised with lysis buffer and proteins reduced and alkylated by addition
of 10 mM TCEP and 20 mM iodoacetamide followed by incubation at RT for 30 min, protected from
light. Samples were then processed using S-Trap micro columns (Protifi). To each sample 10% v/v
H3PO4 was added and samples mixed by vortexing briefly. 6 volumes of 90% methanol HEPES pH
7.1 (loading buffer) were then added and pipette-mixed before loading onto columns using a vac-
uum manifold.
Samples were then washed with 4  150 ml loading buffer. A 1:25 enzyme:protein ratio of LysC/
trypsin mix (Promega) was added to each column in 30 ml of 50 mM HEPES pH 8 with 0.1% sodium
deoxycholate (SDC). Columns were placed into microcentrifuge tubes and incubated for 6 hr at 37˚C
in a Thermomixer S (Eppendorf) without shaking. Open tubes of water were placed in empty posi-
tions and the Thermomixer lid used to minimise evaporation.
After incubation, peptides were eluted in three stages: 40 ml 10 mM HEPES pH 8; 35 ml 0.2% for-
mic acid (FA); then 35 ml 0.2% FA in 50% Acetonitrile (ACN). Samples were dried for a short period
in a vacuum centrifuge to evaporate ACN and then acidified with FA to precipitate SDC. Samples
were then made up to ~100 ml with water, then 600 ml ethyl acetate was added and samples vor-
texed vigorously. After centrifugation at 15000 g for 5 min the lower phase (containing peptides)
was retained and the upper phase (containing SDC and ethyl acetate) was discarded.
After drying fully in a vacuum centrifuge, samples were resuspended in 21 ml 100 mM HEPES pH
8, to which was added 0.2 mg of TMT label dissolved in 9 ml ACN. After 1 hr incubation at RT sam-
ples were analysed by LCMS to ensure complete labelling, then pooled and dried by ~50% in a vac-
uum centrifuge. The pooled sample was made up to ~1 ml in a final concentration of 0.1%
triflouracetic acid (TFA) and the pH was adjusted to <2 with FA. The samples were then subjected to
C18 SPE clean-up using 500 mg Sep-Pak tC18 cartridges (Waters). Columns were wetted with 1 ml
ACN and equilibrated with 3 ml 0.1% TFA before loading the sample, washing with 2 ml 0.1% TFA
and eluting with 250 ml 40% ACN, 250 ml 80% ACN and 250 ml 80% ACN. The eluates were dried in
a vacuum centrifuge.
Off-line high pH reversed-phase (HpRP) peptide fractionation
HpRP fractionation was conducted on an Ultimate 3000 UHPLC system (Thermo Scientific) equipped
with a 2.1 mm 15 cm, 1.7 mm Kinetex EVO C18 column (Phenomenex). Solvent A was 3% ACN,
Solvent B was 100% ACN, and solvent C was 200 mM ammonium formate (pH 10). Throughout the
analysis solvent C was kept at a constant 10%. The flow rate was 400 ml/min and UV was monitored
at 280 nm. Samples were loaded in 90% A for 10 min before a gradient elution of 0–10% B over 10
min (curve 3), 10–34% B over 21 min (curve 5), 34–50% B over 5 min (curve 5) followed by a 10 min
wash with 90% B. 15 s (100 ml) fractions were collected throughout the run. Peptide-containing frac-
tions were orthogonally recombined into 24 (transduced CEM-T4s, experiments 1–2) or 12 (infected
and AFMACS-selected CEM-T4s, experiment 3) fractions, dried in a vacuum centrifuge and stored at
 20˚C prior to analysis.
Mass spectrometry
Data were acquired on an Orbitrap Fusion mass spectrometer (Thermo Scientific) coupled to an Ulti-
mate 3000 RSLC nano UHPLC (Thermo Scientific). Solvent A was 0.1% FA and solvent B was ACN/
0.1% FA. HpRP fractions were resuspended in 20 ml 5% DMSO 0.5% TFA and 10 ml injected. Frac-
tions were loaded at 10 ml/min for 5 min on to an Acclaim PepMap C18 cartridge trap column (300
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mm  5 mm, 5 mm particle size) in 0.1% TFA. After loading, a linear gradient of 3–32% B over 3 hr
was used for sample separation over a column of the same stationary phase (75 mm  50 cm, 2 mm
particle size) before washing with 90% B and re-equilibration. An SPS/MS3 acquisition was used for
all samples and was run as follows. MS1: quadrupole isolation, 120000 resolution, 5  105 AGC tar-
get, 50 msec maximum injection time, ions injected for all parallelisable time. MS2: quadrupole isola-
tion at an isolation width of m/z 0.7, CID fragmentation (NCE 35) with the ion trap scanning out in
rapid mode from m/z 120, 8  103 AGC target, 70 msec maximum injection time, ions accumulated
for all parallelisable time. In synchronous precursor selection mode the top 10 MS2 ions were
selected for HCD fragmentation (65NCE) and scanned out in the orbitrap at 50000 resolution with
an AGC target of 2  104 and a maximum accumulation time of 120 msec, ions were not accumu-
lated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. Dynamic exclu-
sion was set to + /  10 ppm for 90 s, MS2 fragmentation was trigged at 5  103 ions.
Data processing
Spectra were searched using Mascot within Proteome Discoverer 2.2 in two rounds. The first search
was against the UniProt human reference proteome, a custom HIV proteome (adjusted to include
the exact protein coding sequences used) and a compendium of common contaminants (Global Pro-
teome Machine). The second search took all unmatched spectra from the first search and searched
against the human trEMBL database. The following search parameters were used. MS1 tol: 10 ppm;
MS2 tol: 0.6 Da; fixed mods: carbamidomethyl (C) and TMT (N-term, K); var mods: oxidation (M);
enzyme: trypsin (/P). MS3 spectra were used for reporter ion based quantitation with a most confi-
dent centroid tolerance of 20 ppm. PSM FDR was calculated using Mascot percolator and was con-
trolled at 0.01% for ‘high’ confidence PSMs and 0.05% for ‘medium’ confidence PSMs.
Normalisation was automated and based on total s/n in each channel.
The mass spectrometry proteomic data have been deposited to the ProteomeXchange consor-
tium via the PRIDE (Perez-Riverol et al., 2019), partner repository with the dataset identifier
PXD018271 and are summarised in Figure 2—source data 1, Figure 6—source data 1 and Fig-
ure 7—source data 1.
Statistical analysis
Abundances or proteins/peptides satisfying at least a ‘medium’ FDR confidence were subjected to
further analysis in Excel 2016 (Microsoft) and R v.3.6.1 (R Development Core Team, 2019).
For proteomic experiments 1 and 2, abundances in the 3 mock-transduced samples were used to
calculate sample means (x) and standard deviations (S) for each protein. Corresponding protein
abundances in transduced cells were then compared with these values to determine standard scores
(t-scores) for each condition: (X-x)/S (where X represents protein abundance in the condition of inter-
est). Significant outliers were identified by calculating two-tailed p-values using a t-distribution with
2 degrees of freedom. Illustrative t-score/p-value calculations for PPP2R5A in cells transduced with
WT Vif or a control lentivector are shown in Figure 2—figure supplement 2.
For proteomic experiment 3, mean protein abundances in cells infected with DVpr-Vif WT, DVpr-D
Vif, or DVpr-Vif AYR viruses were compared with mean protein abundances in mock-infected cells.
For each pair-wise comparison, a moderated t-test was conducted using the limma R package
(Ritchie et al., 2015; Schwämmle et al., 2013). Benjamini-Hochberg FDR-adjusted p values (q val-
ues) were used to control the false discovery rate.
Antibodies
Antibodies for immunoblot and flow cytometry are detailed in the Key resources table. Anti-HIV-1
Vif (Simon et al., 1995) was obtained from the AIDS Reagent Program, Division of AIDS, NIAID, NIH
(Dr M. H. Malim).
Flow cytometry
Antibody staining
For the flow cytometric screen in 293Ts, a sub-confluent 24-well/condition was harvested with tryp-
sin-EDTA, fixed and permeabilised using the Cytofix/Cytoperm Fixation and Permeabilisation Kit
(BD Biosciences) according to the manufacturer’s instructions. Permeabilised cells were stained with
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AF647-conjugated rabbit anti-HA antibody (Abcam) for 20 min at RT, washed, and analysed with an
LSR Fortessa flow cytometer (BD Biosciences). Doublets were excluded by comparing SSC-W with
SSC-H. Depletion of HA-tagged PPP2R5B, APOBEC3F, or APOBEC3G was quantified by the ratio of
median AF647 fluorescence in GFP+ (transfected, Vif+)/GFP- (untransfected, Vif-) cells for each con-
dition, after deducting background fluorescence of control 293Ts (no HA-tagged protein
expression).
For titration of HIV-AFMACS viruses, typically 2  105 washed CEM-T4s were stained with fluoro-
chrome-conjugated anti-LNGFR and anti-CD4 for 15 min at 4˚C then fixed in PBS/1% paraformalde-
hyde and analysed as above. For titration of lentivectors, GFP fluorescence was quantified without
antibody staining.
DNA content
For cell cycle analysis in transduced CEM-T4s and transduced/transfected HeLas, 1  106 cells/condi-
tion (CEM-T4s) or a 50% confluent 6-well/condition (HeLas) were washed with PBS, then fixed for 30
min with ice-cold 90% methanol. Fixed cells were stained with 7-AAD at 25 mg/ml for 30 mins at 37˚
C, then analysed with an LSR Fortessa flow cytometer (BD Biosciences). Doublets were excluded by
comparing SSC-W with SSC-H. The FlowJo cell cycle platform was used to determine the fraction of
cells in each phase of cell cycle. G2/M cell cycle arrest was quantified by the ratio of cells in G2/M
for each condition, compared with mock-transduced/transfected cells.
For cell cycle analysis in CEM-T4s infected with HIV-AFMACS, cells were first stained with FITC-
conjugated anti-LNGFR (BioLegend), then washed, fixed and stained with 7-AAD and analysed as
above. G2/M cell cycle arrest was quantified by the ratio of cells in G2/M for LNGFR+ (infected, HIV
+)/LNGFR- (uninfected) cells for each condition.
For cell cycle analysis in primary human CD4+ T cells infected with HIV-AFMACS, CD3/CD28
Dynabeads were first removed using a DynaMag-2 magnet (Invitrogen). Cells were stained with
FITC-conjugated anti-LNGFR (BioLegend) and BV421-conjugated anti CD4 (BioLegend), then
washed, fixed, stained with 7-AAD and analysed as above. G2/M cell cycle arrest was quantified by
the ratio of cells in G2/M for LNGFR+ CD4- (infected, HIV+)/LNGFR- CD4+ (uninfected) cells for
each condition.
Immunoblotting
Washed cell pellets were lysed in PBS/2% SDS supplemented with Halt Protease and Phosphatase
Inhibitor Cocktail (Thermo Scientific) and benzonase (Sigma) for 10 min at RT. Post-nuclear superna-
tants were heated in Laemelli Loading Buffer for 5 min at 95 ˚C, separated by SDS-PAGE and trans-
ferred to Immobilon-P membrane (Millipore). Membranes were blocked in PBS/5% non-fat dried
milk (Marvel)/0.2% Tween and probed with the indicated primary antibody overnight at 4 ˚C. Reac-
tive bands were visualised using HRP-conjugated secondary antibodies and SuperSignal West Pico
or Dura chemiluminescent substrates (Thermo Scientific). Typically 10–20 mg total protein was loaded
per lane.
Quantitative reverse transcription PCR
For quantification of PPP2R5 subunit mRNA levels, total RNA was extracted using TRIzol reagent
(Invitrogen), followed by DNase I treatment. cDNA was synthesised using the Superscript III First-
Strand Synthesis System (Invitrogen) with Oligo(dT) (Invitrogen), and 10 ng/test subjected to real-
time PCR using the primers tabulated in Supplementary file 1 (PCR primers for real-time PCR) and
the SYBR Green PCR Master Mix (Thermo Scientific).
To control for PCR efficiency and allow comparison of abundances between different PPP2R5
subunits, standard curves were generated using plasmids encoding PPP2R5A, PPP2R5B, PPP2R5C,
PPP2R5D and PPP2R5E (all Addgene), together with housekeeping gene Tata Binding Protein (TBP,
Source Bioscience). Abundances of different PPP2R5 subunits for each cell type or condition were
derived from the corresponding standard curves, and expressed as mRNA copy numbers relative to
TBP as an endogenous reference.
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Visualization of Vif-CUL5 crystal structure
The previously determined structure of Vif in complex with CUL5, CBFb, and ELOB/C (PDB ID:
4N9F) was used to identify solvent-exposed residues to be mutated in this study (Guo et al., 2014).
Structural analysis and figures were generated using PyMOL Molecular Graphics System, Version 2.0
(Schrödinger).
Bioinformatic analysis of Vif polymorphisms
Protein sequence Web Alignments for Vif, Env, Gag and Nef were downloaded from the Los Alamos
HIV Sequence Alignments Database (accessible at: http://www.hiv.lanl.gov/). The following server
options were selected: Alignment type, Web (all complete sequences); Organism, HIV-1/SIVcpz;
Subtype, M group without recombinants (A-K); DNA/Protein, protein; Year, 2018; Format, FASTA.
These alignments contain all non-recombinant HIV-1 M group sequences from the Los Alamos
HIV Sequence Database, with the following exceptions: only one sequence per patient is included; a
single representative is included of very similar sequences; and sequences unlikely to represent natu-
rally-occurring, viable viruses are excluded. We further subdivided the sequences according to viral
clade (subtype) using the information in the sequence name for example B.FR.83.HXB2 is assigned
to clade B. Analyses were conducted for both clade B viruses and all non-recombinant HIV-1 M
group viruses.
To examine amino acid polymorphism in naturally occurring Vif variants at positions correspond-
ing to residues 31, 33/34 and 128 of NL4-3 Vif, sequence logos were generated using WebLogo
(Crooks et al., 2004). Further data analysis was conducted in R v.3.6.1 (R Development Core Team,
2019). In brief, residues at each position of interest were extracted using the seqinr R package
(Charif and Lobry, 2007), then frequencies were calculated and graphical summaries generated
using the ggplot R package (Wickham, 2009). To identify covariance (non-random association)
between polymorphisms at positions 31 and 128, 2  2 contingency tables comparing frequencies
of key residue pairs were constructed, then subjected to two-tailed Fisher’s exact tests of indepen-
dence (Wang and Lee, 2007).
To construct phylogenetic trees, only viruses with protein sequences available for all of Vif, Env,
Gag and Nef were included. This enabled direct comparison of trees based on different viral pro-
teins. Multiple sequence alignments and phylogenetic tree data (in Newick format) for each viral pro-
tein were generated using the Clustal Omega web server (Sievers and Higgins, 2014), then
visualised using the ggtree R package (Yu et al., 2018).
All alignment and sequence files, scripts and details of the bioinformatic analyses described here
are available at: https://github.com/annaprotasio/Marelli_et_al_HIV_Vif (copy archived at https://
github.com/elifesciences-publications/Marelli_et_al_HIV_Vif).
General statistical analysis
Where indicated, Student’s t-tests (unpaired two-sample, assuming homoscedasticity, two-tailed),
Fisher’s exact tests (two-tailed) and 95% confidence intervals were calculated using Prism 7.0
(GraphPad). General data manipulation was conducted using Excel 2016 (Microsoft).
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